EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SGLT2 Inhibition Combined with Zn Supplementation Protects the Liver-Pancreas Axis in Experimental Type 2 Diabetes

Irina Claudia Anton iD, Carmen Solcan iD, Liliana Mititelu-Tartau iD, Cornelia Amalinei iD, Mihaela Poroch iD, Vladimir Poroch iD, Beatrice Rozalina Buca iD, Cosmin-Gabriel Tartau iD, Ana-Maria Pelin iD, Alexandra Jitareanu, Mihail Virgil Boldeanu iD, Gina Eosefina Botnariu iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27209067 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Irina Claudia Anton und 11 weiteren Autor:innen. Beteiligte Einrichtung: Grigore T. Popa, University of Medicine and Pharmacy, Universitatii St. 16, 700115 Iasi, Romania. Hauptthemen laut MEDLINE: Liver, Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Experimental, Pancreas. Die Arbeit nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Social Fund, Doctoral School of “Grigore T. Popa” University of Medicine and Pharmacy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type 2 diabetes mellitus (T2DM) is associated with chronic hyperglycemia, inflammation, and progressive hepatic and pancreatic dysfunction. Although sodium-glucose cotransporter 2 (SGLT2) inhibitors exert metabolic and organ-protective effects, their ability to preserve pancreatic architecture and attenuate diabetes-associated hepatic injury, particularly combined with nutritional interventions, remains insufficiently explored. This study investigated the protective effects of dapagliflozin (DAPA) and empagliflozin (EMPA), alone or combined with zinc (Zn), on hepatic and pancreatic alterations in experimental diabetes. Methods: Diabetes was induced in male Sprague–Dawley rats using streptozotocin (STZ) and high fat diet (HFD). Diabetic animals received DAPA, EMPA, Zn, or SGLT2 inhibitor–Zn combinations for four weeks. Hepatic biochemical parameters, lipid profile, histopathology, pancreatic morphometry, and insulin immunoreactivity were evaluated. Diabetes induced hepatic and pancreatic alterations, including elevated liver injury markers, hepatocellular degeneration, reduced islet number and β-cell density, and diminished insulin immunoreactivity. DAPA and EMPA attenuated these changes, with greater improvements following Zn combination therapy. EMPA + Zn produced the most favorable response, improving hepatic architecture, reducing VCAM-1, ICAM-1, and NF-κB expression, preserving islet morphology, increasing β-cell density, and enhancing insulin immunoreactivity. SGLT2 inhibitors attenuated diabetes-associated hepatic and pancreatic alterations in this experimental model, while Zn supplementation was associated with additional tissue-preserving effects, particularly when combined with EMPA. These findings support further investigation of combined SGLT2 inhibition and Zn supplementation as an experimental approach to diabetes-associated organ injury; however, their clinical relevance remains to be established.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LiverSodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, ExperimentalPancreasZincDiabetes Mellitus, Type 2AnimalsMaleRatsRats, Sprague-DawleyDietary SupplementsBenzhydryl CompoundsGlucosidesDiet, High-FatSodium-Glucose Transporter 2Insulin

Stichwörter der Autor:innen

DAPAEMPASGLT2 inhibitorsZn supplementationhepatic injurypancreatic β-cellstype 2 diabetes mellitus

Substanzen

Sodium-Glucose Transporter 2 InhibitorsZincBenzhydryl CompoundsempagliflozinGlucosidesdapagliflozinSodium-Glucose Transporter 2Insulin

Autor:innen und Institutionen

  • Grigore T. Popa, University of Medicine and Pharmacy, Universitatii St. 16, 700115 Iasi, Romania.
  • Ion Ionescu de la Brad University of Life Sciences, Aleea Mihail Sadoveanu No. 3, 700490 Iasi, Romania.
  • Dunarea de Jos University, 800010 Galati, Romania.
  • University of Medicine and Pharmacy Craiova, 200349 Craiova, Romania.

ORCID-Profile: Irina Claudia Anton, Carmen Solcan, Liliana Mititelu-Tartau, Cornelia Amalinei, Mihaela Poroch, Vladimir Poroch, Beatrice Rozalina Buca, Cosmin-Gabriel Tartau, Ana-Maria Pelin, Mihail Virgil Boldeanu, Gina Eosefina Botnariu

Förderung

  • European Social Fund
  • Doctoral School of “Grigore T. Popa” University of Medicine and Pharmacy

Zitieren

APA

Anton, I. C., Solcan, C., Mititelu-Tartau, L., Amalinei, C., Poroch, M., Poroch, V., Buca, B. R., Tartau, C. G., Pelin, A. M., Jitareanu, A., Boldeanu, M. V., & Botnariu, G. E. (2026). SGLT2 Inhibition Combined with Zn Supplementation Protects the Liver-Pancreas Axis in Experimental Type 2 Diabetes. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27209067

Vancouver

Anton IC, Solcan C, Mititelu-Tartau L, Amalinei C, Poroch M, Poroch V, et al. SGLT2 Inhibition Combined with Zn Supplementation Protects the Liver-Pancreas Axis in Experimental Type 2 Diabetes. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27209067

BibTeX
@article{Anton2026,
  author = {Anton, Irina Claudia and Solcan, Carmen and Mititelu-Tartau, Liliana and Amalinei, Cornelia and Poroch, Mihaela and Poroch, Vladimir and Buca, Beatrice Rozalina and Tartau, Cosmin-Gabriel and Pelin, Ana-Maria and Jitareanu, Alexandra and Boldeanu, Mihail Virgil and Botnariu, Gina Eosefina},
  title = {SGLT2 Inhibition Combined with Zn Supplementation Protects the Liver-Pancreas Axis in Experimental Type 2 Diabetes},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27209067}
}
Kostenlos starten →